LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Zimmer Recalls M/L Taper Hip Stems and Necks
Legal & Regulatory and Reimbursement

Zimmer Recalls M/L Taper Hip Stems and Necks

July 7, 2015 2 min read Premium comments

Advertisement

Zimmer Recalls M/L Taper Hip Stems and Necks
M/L Taper Hip Prosthesis / Source: Zimmer, Inc.
Secondary

On June 8, 2015, Zimmer Inc. initiated a Class I Recall of its M/L Taper with Kinectiv Technology Femoral Stems and Necks.

Manufacturing Residue

Due to a process monitoring failure, higher-than-expected amounts of manufacturing residues were left on the devices made fromMarch 31, 2015 through April 20, 2015. The residues can cause “serious adverse health issues including allergic reactions, pain, infections, or death. Use of these products may require the need for a revision surgery to replace the affected implant, ” according to the company.

The stems and necks are Tivanium alloy implants used for hip replacements that allow the surgeon to fit the implant specifically to the patient.

According to the FDA, Zimmer issued recall notification letters and instructions for distributors and hospital staff on May 18, 2015.

Recall Instructions

The following instructions were given to distributors:

  • “Review the notification and ensure affected personnel are aware of the contents.”
  • “Locate all affected product identified in the recall letter and quarantine them immediately.”
  • “Carry out a physical count of all affected product in your territory and complete the Inventory Return Certification Form sent by the company. Email a completed copy of the form to postmarket@zimmer.com.”
  • “Return the recalled product along with the completed Inventory Return Certification Form.”

Distributors were asked to notify the company of any hospitals to which they “further distributed the affected product. “In addition, ” distributors were asked to “identify the surgeons that have implanted this product. Supply that information to the company using the provided spreadsheet template.”

Advertisement

Instructions for hospital staff, including risk managers and surgeons, included:

  • “Review the notification and ensure affected personnel are aware of the contents.”
  • “Assist your Zimmer sales representative with the quarantine of any affected product.”
  • “Your Zimmer sales representative will remove the recalled product from the facility.”

Kinectiv Technology

According to the company, the keystone to Kinectiv technology is the “exclusive use of +0 femoral heads. This allows independent adjustment of leg length and offset since all adjustments are made with the necks. Leg length is of primary concern in total joint replacement for surgeons and patients. Kinectiv Technology allows the surgeon to optimize leg length without affecting offset and conversely offset without affecting leg length.”

Range of motion and joint stability, says the company, is another primary issue. “With the exclusive use of the +0 head, every neck has been optimized to this head length to maximize range of motion. In addition, the ante/retroverted necks allow the surgeon to intraoperatively fine tune the range of motion depending on the patient anatomy and implant position.”

Contacting Zimmer and FDA

If you have questions, contact the Zimmer customer call center at 1-877-946-2761 between 8:00 am and 5:00 pm EST with any questions or concerns.

The FDA encourages healthcare professionals and patients to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

Complete and submit the report Online: www.fda.gov/MedWatch/report.

Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy